EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Prelude Therapeutics Incorporated (PRLD) had EBITDA Margin of -850.30% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$12.14M |
|
$-99.50M |
|
-- |
|
$12.14M |
|
$116.71M |
|
$-104.57M |
|
$5.07M |
|
$-99.50M |
|
$-99.50M |
|
$-99.50M |
|
$-99.50M |
|
$-99.50M |
|
$-99.50M |
|
$-104.57M |
|
$-103.23M |
|
76.96M |
|
76.96M |
|
$-1.29 |
|
$-1.29 |
|
| Balance Sheet Financials | |
$105.69M |
|
$5.11M |
|
$35.62M |
|
$141.31M |
|
$52.99M |
|
-- |
|
$19.68M |
|
$72.68M |
|
$68.64M |
|
$68.64M |
|
$68.64M |
|
62.95M |
|
| Cash Flow Statement Financials | |
$-56.30M |
|
$53.46M |
|
$24.82M |
|
$16.52M |
|
$38.49M |
|
$21.97M |
|
$11.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-861.33% |
|
-861.33% |
|
|
EBITDA Margin |
-850.30% |
-819.59% |
|
-819.59% |
|
$-56.37M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-144.96% |
|
-144.96% |
|
-70.41% |
|
-144.96% |
|
$1.09 |
|
$-0.73 |
|
$-0.73 |
|